Nu.Q® Discover: Work with us to access our range of proprietary, state-of-the-art assays and answer your drug development, pre-clinical and clinical questions.

How we can help: Nu.Q® Discover is a complete solution to profiling nucleosomes and empowers drug developers and scientists offering rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies – from drug discovery to market ready.

Nu.Q® Discover is an invaluable research tool for R&D professionals working within the field of Pharmacoepigenetics, studying the epigenetic basis for variation in response to drugs.

Applications

Nu.Q® Discover is built on Volition’s cutting-edge Nu.Q® nucleosome quantification technology and adds value across the drug development pipeline, with applications in:

• Oncology
• Neurodegenerative diseases
• Autoimmune diseases
• NETosis

Use our Nu.Q® Discover assays to test sensitively for circulating nucleosomes and gain deep insights into how drug actions are impacted by epigenetic alterations. Our biomarkers support the entire drug discovery and development process from pre-clinical testing to market-ready.

Case study: Our assays in action

Client: ORIC Pharmaceuticals

Project: Pharmacodynamics (PD) biomarker

We worked with ORIC Pharmaceuticals and demonstrated how the Nu.Q® Discover cell-free (cf)-nucleosomal H3K27me3 assay enables robust, quantitative analysis of histone modifications in circulating cf-nucleosomes.

Findings:

• A method of choice for quantification of plasma cf-nucleosome H3K27me3 levels.
• The assay has shown small molecule inhibition of PRC2 in a manner that is:
• Dose dependent
• Time dependent
• Tumor selective
• The assay is non-invasive and allows for serial sample collection from patients.
• No requirements for further optimization by the investigator / sponsor of the trial.
• Once samples have arrived at Volition, the turnaround time for results is fast < 1 week.

Download the poster